Expert opinion on meningococcal B vaccine – information and suggestions to EU/EEA countries
The ECDC expert opinion provides information on the burden of serogroup B invasive meningococcal disease in the EU/EEA, includes general considerations for 4CMenB introduction such as vaccine immunogenicity, safety, cost-effectiveness, ease of implementation and areas for country collaboration, and highlights different options for vaccine introduction.
Expert panel reviews neuraminidase inhibitors for the prevention and treatment of influenza
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.
ECDC Zika epidemic rapid risk assessment includes updated risk classification approach
The latest update of ECDC’s rapid risk assessment on the Zika epidemic includes an assessment of the level of risk for travellers based on an adaptation of the WHO interim guidance on the Zika virus country classification scheme and the recent epidemiological and scientific information.
New rapid risk assessment on Crimean-Congo haemorrhagic fever in Spain
On 31 August 2016 Spain reported two cases of infection with Crimean–Congo haemorrhagic fever (CCHF). These are the first autochthonous clinical cases of CCHF in Spain and in south-western Europe, and accordingly ECDC has published a rapid risk assessment on the event.